Morphic’s lead program is an oral treatment for inflammatory bowel disease patients, according to a July 8 news release.
The molecule is also being evaluated to treat patients with ulcerative colitis and Crohn’s disease.
The transaction has been approved by the boards of directors of both com
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
